GAGE13

Across TCGA pan-cancer cohorts, GAGE13 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated GAGE13 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GAGE13 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GAGE13 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, STAD, and UVM are the cancer types where GAGE13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.216	0.726	<.001	108	view →
STAD	OS	Tertile	IV	0.111	0.433	.002	54	view →
UVM	OS	Tertile	All	0.220	0.917	<.001	54	view →
KIRP	OS	Tertile	All	0.178	0.885	<.001	54	view →
UCS	DFS	Tertile	IV	0.132	0.718	.002	36	view →
PAAD	DFS	Tertile	All	0.173	0.485	.031	18	view →
LUAD	OS	Tertile	All	0.391	0.701	.023	12	view →
SCLC	OS	Tertile	All	0.219	0.650	.031	9	view →
BLCA	DFS	Tertile	III,IV	0.630	0.265	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

GAGE13–LIHC (OS)

Open the LIHC breakdown →